Read Gene

Read Gene Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Read Gene (RDG.WA) as of Oct 16, 2026 is -127.52 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -188.20 % — a change of -32.24% (higher).

Cash Conversion

-127.52 %

YoY

-32.24%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Read Gene is 2025 -127.52 % . Cash Conversion Rate (OCF/Net Income) of Read Gene was 2024 -188.20 % . It decreases by -32.24% higher compared to the previous year.

The Read Gene Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-42.40 PLN
Jan 1, 2019
3,250.76 PLN
Jan 1, 2020
473.33 PLN
Jan 1, 2021
280.49 PLN
Jan 1, 2022
163.16 PLN
Jan 1, 2023
60.96 PLN
Jan 1, 2024
-188.20 PLN
Jan 1, 2025
-127.52 PLN
The Read Gene Cash Conversion history
YEARCash ConversionYoY
-127.52 %-32.24%
-188.20 %-408.74%
60.96 %-62.64%
163.16 %-41.83%
280.49 %-40.74%
473.33 %-85.44%
3,250.76 %-7,766.51%
-42.40 %-105.40%
785.11 %-905.14%
-97.51 %-192.45%
105.47 %-64.07%
293.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA is a biotechnology company based in Szczecin, Poland, operating within the Health Care sector. The company went public via an IPO on February 12, 2009, and is listed under the ticker RDG.WA with ISIN PLRADGN00014. Read Gene SA focuses on medical research and testing, particularly in the fields of chemoprevention, clinical trials, and genetic testing. Its services include specialized tests for breast cancer, colon cancer, and prostate cancer, alongside medical consultancy and DNA testing. The company also provides DNA-related supplements. It operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o., and its major shareholder is GEN-PAT-MED Sp. z o.o. The company's headquarters are located in Szczecin, within the West Pomeranian Voivodeship. Read Gene SA's activities are centered on developing technologies aimed at detecting, preventing, and treating malignant tumors. The company's website is https://read-gene.com/. No additional details regarding founding year, specific products, or financial figures are provided in the source material. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Cash Conversion Rate (OCF/Net Income) of Read Gene is -127.52 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Read Gene changed from -188.20 % to -127.52 %, representing a -32.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Read Gene since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Read Gene

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Read Gene